<?xml version='1.0' encoding='utf-8'?>
<document id="10421617"><sentence text="Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction."><entity charOffset="125-134" id="DDI-PubMed.10421617.s1.e0" text="ritonavir" /></sentence><sentence text="ABT-378 is a potent in vitro inhibitor of the HIV protease and is currently being developed for coadministration with another HIV protease inhibitor, ritonavir, as an oral therapeutic treatment for HIV infection"><entity charOffset="150-159" id="DDI-PubMed.10421617.s2.e0" text="ritonavir" /></sentence><sentence text=" In the present study, the effect of ritonavir, a potent inhibitor of cytochrome P-450 (CYP) 3A, on the in vitro metabolism of ABT-378 was examined"><entity charOffset="37-46" id="DDI-PubMed.10421617.s3.e0" text="ritonavir" /></sentence><sentence text=" Furthermore, the effect of ABT-378-ritonavir combinations on several CYP-dependent monooxygenase activities in human liver microsomes was also examined"><entity charOffset="28-45" id="DDI-PubMed.10421617.s4.e0" text="ABT-378-ritonavir" /></sentence><sentence text=" ABT-378 was found to undergo NADPH- and CYP3A4/5-dependent metabolism to three major metabolites, M-1 (4-oxo) and M-3/M-4 (4-hydroxy epimers), as well as several minor oxidative metabolites in human liver microsomes" /><sentence text=" The mean apparent K(m) and V(max) values for the metabolism of ABT-378 by human liver microsomes were 6" /><sentence text="8 +/- 3" /><sentence text="6 microM and 9" /><sentence text="4 +/- 5" /><sentence text="5 nmol of ABT-378 metabolized/mg protein/min, respectively" /><sentence text=" Ritonavir inhibited human liver microsomal metabolism of ABT-378 potently (K(i) = 0" /><sentence text="013 microM)" /><sentence text=" The combination of ABT-378 and ritonavir was much weaker in inhibiting CYP-mediated biotransformations than ritonavir alone, and the inhibitory effect appears to be primarily due to the ritonavir component of the combination"><entity charOffset="20-27" id="DDI-PubMed.10421617.s13.e0" text="ABT-378" /><entity charOffset="32-41" id="DDI-PubMed.10421617.s13.e1" text="ritonavir" /><entity charOffset="109-118" id="DDI-PubMed.10421617.s13.e2" text="ritonavir" /><entity charOffset="187-196" id="DDI-PubMed.10421617.s13.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.10421617.s13.e0" e2="DDI-PubMed.10421617.s13.e0" /><pair ddi="false" e1="DDI-PubMed.10421617.s13.e0" e2="DDI-PubMed.10421617.s13.e1" /><pair ddi="false" e1="DDI-PubMed.10421617.s13.e0" e2="DDI-PubMed.10421617.s13.e2" /><pair ddi="false" e1="DDI-PubMed.10421617.s13.e0" e2="DDI-PubMed.10421617.s13.e3" /><pair ddi="false" e1="DDI-PubMed.10421617.s13.e1" e2="DDI-PubMed.10421617.s13.e1" /><pair ddi="false" e1="DDI-PubMed.10421617.s13.e1" e2="DDI-PubMed.10421617.s13.e2" /><pair ddi="false" e1="DDI-PubMed.10421617.s13.e1" e2="DDI-PubMed.10421617.s13.e3" /><pair ddi="false" e1="DDI-PubMed.10421617.s13.e2" e2="DDI-PubMed.10421617.s13.e2" /><pair ddi="false" e1="DDI-PubMed.10421617.s13.e2" e2="DDI-PubMed.10421617.s13.e3" /></sentence><sentence text=" The ABT-378-ritonavir combinations (at 3:1 and 29:1 ratios) inhibited CYP3A (IC(50) = 1"><entity charOffset="5-22" id="DDI-PubMed.10421617.s14.e0" text="ABT-378-ritonavir" /></sentence><sentence text="1 and 4" /><sentence text="6 microM), albeit less potently than ritonavir (IC(50) = 0"><entity charOffset="37-46" id="DDI-PubMed.10421617.s16.e0" text="ritonavir" /></sentence><sentence text="14 microM)" /><sentence text=" Metabolic reactions mediated by CYP1A2, CYP2A6, and CYP2E1 were not affected by the ABT-378-ritonavir combinations" /><sentence text=" The inhibitory effects of ABT-378-ritonavir combinations on CYP2B6 (IC(50) = &gt;30 microM), CYP2C9 (IC(50) = 13"><entity charOffset="27-44" id="DDI-PubMed.10421617.s19.e0" text="ABT-378-ritonavir" /></sentence><sentence text="7 and 23" /><sentence text="0 microM), CYP2C19 (IC(50) = 28" /><sentence text="7 and 38" /><sentence text="0 microM), and CYP2D6 (IC(50) = 13" /><sentence text="5 and 29" /><sentence text="0 microM) were marginal and are not likely to produce clinically significant drug-drug interactions" /><sentence text="" /></document>